Your Cart

Rights Commence Trading

Rights Commence Trading

Imagion Biosystems Limited (ASX: IBX) (the Company), is pleased to confirm that the rights associated with the Company’s Renounceable Rights Issue announced on 28 October 2019 have commenced trading on a deferred basis under the ASX ticker IBXR.
Under the Rights Issue timetable the rights trading will end on 8 November 2019.
Read Rights Commence Trading.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.